Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.86)
# 1,586
Out of 5,126 analysts
46
Total ratings
40%
Success rate
53.86%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $2.5 | $0.78 | +220.55% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $11.10 | +62.16% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $10.42 | +43.95% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.60 | +1,087.50% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $10.14 | +195.86% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.09 | +1,918.35% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $8.06 | +197.95% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $23.44 | +433.28% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.54 | +408.47% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.60 | +630.77% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.42 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $159.32 | -50.31% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $103.18 | +50.22% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.86 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.12 | +701.28% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $3.36 | +53,471.43% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $36.19 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.61 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.16 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $3.04 | +49,242.11% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.15 | +78,160.87% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.25 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $9.52 | +1,633.19% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.13 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.33 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $2.5
Current: $0.78
Upside: +220.55%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $11.10
Upside: +62.16%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $10.42
Upside: +43.95%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.60
Upside: +1,087.50%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $10.14
Upside: +195.86%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.09
Upside: +1,918.35%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $8.06
Upside: +197.95%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $23.44
Upside: +433.28%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.54
Upside: +408.47%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.60
Upside: +630.77%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.42
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $159.32
Upside: -50.31%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $103.18
Upside: +50.22%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $8.86
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.12
Upside: +701.28%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $3.36
Upside: +53,471.43%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $36.19
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.61
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.16
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $3.04
Upside: +49,242.11%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.15
Upside: +78,160.87%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.25
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $9.52
Upside: +1,633.19%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $5.13
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.33
Upside: -